Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage- a prospective clinical observation

Zhong-Min Li; Zhi-Ti Zhang; Chuan-Jun Guo; Feng-Jun Geng; Fu Qiang; Lexin Wang

doi:10.1016/j.clineuro.2012.04.030

Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage- a prospective clinical observation

Zhong-Min Li, Zhi-Ti Zhang, Chuan-Jun Guo, Feng-Jun Geng, Fu Qiang, Lexin Wang

Science and Health

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

35 Downloads (Pure)

Abstract

BackgroundThis study was designed to assess the clinical effect of bone marrow mononuclear cells including mesenchymal stem cell (MSCs) in patients with intracerebral hemorrhage (ICH).MethodsOne hundred patients were divided into a study (n=60) or a control group (n=40). Bone marrow mononuclear cells from the same patient were injected to the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.9days after ICH. National Institute Stroke Scale (NIHSSS) and Barthel index was used to assess neurologic impairment and daily activities, respectively, before and 6months after intervention.ResultsSix months after implantation, the NIHSS score in the study group was lower than in the control group (10.09±8.86 vs 14.35±10.14, P<0.01), whereas the Barthel scores were higher (57.39±23.51 vs 46.90±20.29, P<0.01). Neurological and functional improvement was observed in 52 (86.7%) of the study group patients, and in 17 (42.5%) of the control group patients (P=0.001). No allergic or other adverse effects were observed in the study group.ConclusionAutologous bone marrow mononuclear cell implantation reduced neurological impairment and improved activities of daily living in a selected group of ICH patients. Further studies are required to ascertain the long-term safety and efficacy of this treatment.

Original language	English
Pages (from-to)	72-76
Number of pages	5
Journal	Clinical Neurology and Neurosurgery
Volume	115
Issue number	1
DOIs	https://doi.org/10.1016/j.clineuro.2012.04.030
Publication status	Published - Jan 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clineuro.2012.04.030

Li Clinical Neurology Neurosurg revision2.docAccepted author manuscript, 268 KB

Cite this

@article{5ead529e7a3c4326ab91818d53248713,

title = "Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage- a prospective clinical observation",

abstract = "BackgroundThis study was designed to assess the clinical effect of bone marrow mononuclear cells including mesenchymal stem cell (MSCs) in patients with intracerebral hemorrhage (ICH).MethodsOne hundred patients were divided into a study (n=60) or a control group (n=40). Bone marrow mononuclear cells from the same patient were injected to the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.9days after ICH. National Institute Stroke Scale (NIHSSS) and Barthel index was used to assess neurologic impairment and daily activities, respectively, before and 6months after intervention.ResultsSix months after implantation, the NIHSS score in the study group was lower than in the control group (10.09±8.86 vs 14.35±10.14, P<0.01), whereas the Barthel scores were higher (57.39±23.51 vs 46.90±20.29, P<0.01). Neurological and functional improvement was observed in 52 (86.7%) of the study group patients, and in 17 (42.5%) of the control group patients (P=0.001). No allergic or other adverse effects were observed in the study group.ConclusionAutologous bone marrow mononuclear cell implantation reduced neurological impairment and improved activities of daily living in a selected group of ICH patients. Further studies are required to ascertain the long-term safety and efficacy of this treatment.",

keywords = "Open access version available, Bone marrow, Intracerebral hemorrhage, Mesenchymal stem cell, Stroke",

author = "Zhong-Min Li and Zhi-Ti Zhang and Chuan-Jun Guo and Feng-Jun Geng and Fu Qiang and Lexin Wang",

note = "Imported on 12 Apr 2017 - DigiTool details were: month (773h) = January, 2013; Journal title (773t) = Clinical Neurology and Neurosurgery. ISSNs: 0303-8467; ",

year = "2013",

month = jan,

doi = "10.1016/j.clineuro.2012.04.030",

language = "English",

volume = "115",

pages = "72--76",

journal = "Clinical Neurology and Neurosurgery",

issn = "0303-8467",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage- a prospective clinical observation

AU - Li, Zhong-Min

AU - Zhang, Zhi-Ti

AU - Guo, Chuan-Jun

AU - Geng, Feng-Jun

AU - Qiang, Fu

AU - Wang, Lexin

N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = January, 2013; Journal title (773t) = Clinical Neurology and Neurosurgery. ISSNs: 0303-8467;

PY - 2013/1

Y1 - 2013/1

N2 - BackgroundThis study was designed to assess the clinical effect of bone marrow mononuclear cells including mesenchymal stem cell (MSCs) in patients with intracerebral hemorrhage (ICH).MethodsOne hundred patients were divided into a study (n=60) or a control group (n=40). Bone marrow mononuclear cells from the same patient were injected to the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.9days after ICH. National Institute Stroke Scale (NIHSSS) and Barthel index was used to assess neurologic impairment and daily activities, respectively, before and 6months after intervention.ResultsSix months after implantation, the NIHSS score in the study group was lower than in the control group (10.09±8.86 vs 14.35±10.14, P<0.01), whereas the Barthel scores were higher (57.39±23.51 vs 46.90±20.29, P<0.01). Neurological and functional improvement was observed in 52 (86.7%) of the study group patients, and in 17 (42.5%) of the control group patients (P=0.001). No allergic or other adverse effects were observed in the study group.ConclusionAutologous bone marrow mononuclear cell implantation reduced neurological impairment and improved activities of daily living in a selected group of ICH patients. Further studies are required to ascertain the long-term safety and efficacy of this treatment.

AB - BackgroundThis study was designed to assess the clinical effect of bone marrow mononuclear cells including mesenchymal stem cell (MSCs) in patients with intracerebral hemorrhage (ICH).MethodsOne hundred patients were divided into a study (n=60) or a control group (n=40). Bone marrow mononuclear cells from the same patient were injected to the perihemorrhage area in the base ganglia through an intracranial drainage tube 5.9days after ICH. National Institute Stroke Scale (NIHSSS) and Barthel index was used to assess neurologic impairment and daily activities, respectively, before and 6months after intervention.ResultsSix months after implantation, the NIHSS score in the study group was lower than in the control group (10.09±8.86 vs 14.35±10.14, P<0.01), whereas the Barthel scores were higher (57.39±23.51 vs 46.90±20.29, P<0.01). Neurological and functional improvement was observed in 52 (86.7%) of the study group patients, and in 17 (42.5%) of the control group patients (P=0.001). No allergic or other adverse effects were observed in the study group.ConclusionAutologous bone marrow mononuclear cell implantation reduced neurological impairment and improved activities of daily living in a selected group of ICH patients. Further studies are required to ascertain the long-term safety and efficacy of this treatment.

KW - Open access version available

KW - Bone marrow

KW - Intracerebral hemorrhage

KW - Mesenchymal stem cell

KW - Stroke

U2 - 10.1016/j.clineuro.2012.04.030

DO - 10.1016/j.clineuro.2012.04.030

M3 - Article

C2 - 22657095

SN - 0303-8467

VL - 115

SP - 72

EP - 76

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

IS - 1

ER -

Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage- a prospective clinical observation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this